ProQR Therapeutics (NASDAQ:PRQR) Receives Buy Rating from Chardan Capital

Chardan Capital restated their buy rating on shares of ProQR Therapeutics (NASDAQ:PRQR) in a research note released on Thursday,Benzinga reports. They currently have a $4.00 price target on the biopharmaceutical company’s stock.

A number of other analysts have also recently weighed in on the company. StockNews.com cut ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. HC Wainwright raised their target price on ProQR Therapeutics from $5.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Finally, Raymond James upgraded ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their target price for the stock from $6.00 to $14.00 in a research note on Tuesday, October 29th. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $7.60.

ProQR Therapeutics Trading Down 14.0 %

Shares of NASDAQ:PRQR opened at $2.83 on Thursday. The company has a market cap of $231.15 million, a PE ratio of -8.84 and a beta of 0.24. The company’s 50 day moving average is $3.40 and its two-hundred day moving average is $2.40. ProQR Therapeutics has a 52 week low of $1.61 and a 52 week high of $4.62.

Hedge Funds Weigh In On ProQR Therapeutics

Several hedge funds have recently made changes to their positions in PRQR. OneDigital Investment Advisors LLC lifted its holdings in shares of ProQR Therapeutics by 37.0% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 15,550 shares during the last quarter. BNP Paribas Financial Markets increased its position in ProQR Therapeutics by 14.2% during the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 7,300 shares during the period. Finally, Privium Fund Management B.V. lifted its stake in ProQR Therapeutics by 4.4% in the second quarter. Privium Fund Management B.V. now owns 5,580,725 shares of the biopharmaceutical company’s stock valued at $9,208,000 after buying an additional 236,279 shares during the last quarter. Hedge funds and other institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).